Skip to main content
Erschienen in:

24.01.2022 | Original Article

The acidic domain of Hmga2 and the domain’s linker region are critical for driving self-renewal of hematopoietic stem cell

verfasst von: Yuqi Sun, Sho Kubota, Mihoko Iimori, Ai Hamashima, Haruka Murakami, Jie Bai, Mariko Morii, Takako Yokomizo-Nakano, Motomi Osato, Kimi Araki, Goro Sashida

Erschienen in: International Journal of Hematology | Ausgabe 4/2022

Einloggen, um Zugang zu erhalten

Abstract

High mobility group AT-hook 2 (Hmga2) is a chromatin modifier protein that plays a critical role in fetal development and leukemia propagation by binding to chromatin and DNA via its AT-hook domains. However, the molecular mechanisms by which Hmga2 activates the expression of target genes to drive the self-renewal of hematopoietic stem cells (HSCs) remain unclear. We generated Rosa26 locus Hmga2 conditional knock-in mice and found that overexpression of Hmga2 promoted self-renewal of normal HSCs, but maintained their fitness in bone marrow, and consequently was not sufficient to initiate malignancy. This result is consistent with previous findings showing that Hmga2 is a proto-oncogene. We also assessed the cellular functions of Hmga2 mutants lacking functional domains and demonstrated that the C-terminus acidic domain of Hmga2 and the domain’s linker region were critical for activating genes involved in stem cell signatures, such as the Igf2bp2 gene, to drive proliferation of HSCs. In contrast, overexpression of Hmga1, a member of the Hmga family with a different linker region, did not drive proliferation of HSCs. Our results reveal a critical role for the acidic domain of Hmga2 and the domain’s linker region in modulating the transcription and self-renewal functions of HSCs.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Fusco A, Fedele M. Roles of HMGA proteins in cancer. Nat Rev Cancer. 2007;7(12):899–910.CrossRef Fusco A, Fedele M. Roles of HMGA proteins in cancer. Nat Rev Cancer. 2007;7(12):899–910.CrossRef
2.
Zurück zum Zitat Cleynen I, Van de Ven WJM. The HMGA proteins: a myriad of functions. Int J Oncol. 2008;32(2):289–305.PubMed Cleynen I, Van de Ven WJM. The HMGA proteins: a myriad of functions. Int J Oncol. 2008;32(2):289–305.PubMed
3.
Zurück zum Zitat Thomsen MS, Franssen L, Launholt D, Fojan P, Grasser KD. Interactions of the basic N-terminal and the acidic C-terminal domains of the maize chromosomal HMGB1 protein. Biochemistry. 2004;43(25):8029–37.CrossRef Thomsen MS, Franssen L, Launholt D, Fojan P, Grasser KD. Interactions of the basic N-terminal and the acidic C-terminal domains of the maize chromosomal HMGB1 protein. Biochemistry. 2004;43(25):8029–37.CrossRef
4.
Zurück zum Zitat Malarkey CS, Churchill MEA. The high mobility group box: the ultimate utility player of a cell. Trends Biochem Sci. 2012;37(12):553–62.CrossRef Malarkey CS, Churchill MEA. The high mobility group box: the ultimate utility player of a cell. Trends Biochem Sci. 2012;37(12):553–62.CrossRef
5.
Zurück zum Zitat Oshima M, Hasegawa N, Mochizuki-Kashio M, Muto T, Miyagi S, Koide S, et al. Ezh2 regulates the Lin28/let-7 pathway to restrict activation of fetal gene signature in adult hematopoietic stem cells. Exp Hematol. 2016;44(4):282-296.e3.CrossRef Oshima M, Hasegawa N, Mochizuki-Kashio M, Muto T, Miyagi S, Koide S, et al. Ezh2 regulates the Lin28/let-7 pathway to restrict activation of fetal gene signature in adult hematopoietic stem cells. Exp Hematol. 2016;44(4):282-296.e3.CrossRef
6.
Zurück zum Zitat Rowe RG, Wang LD, Coma S, Han A, Mathieu R, Pearson DS, et al. Developmental regulation of myeloerythroid progenitor function by the Lin28b–let-7–Hmga2 axis. J Exp Med. 2016;213(8):1497–512.CrossRef Rowe RG, Wang LD, Coma S, Han A, Mathieu R, Pearson DS, et al. Developmental regulation of myeloerythroid progenitor function by the Lin28b–let-7–Hmga2 axis. J Exp Med. 2016;213(8):1497–512.CrossRef
7.
Zurück zum Zitat Sashida G, Wang C, Tomioka T, Oshima M, Aoyama K, Kanai A, et al. The loss of Ezh2 drives the pathogenesis of myelofibrosis and sensitizes tumor-initiating cells to bromodomain inhibition. J Exp Med. 2016;213(8):1459–77.CrossRef Sashida G, Wang C, Tomioka T, Oshima M, Aoyama K, Kanai A, et al. The loss of Ezh2 drives the pathogenesis of myelofibrosis and sensitizes tumor-initiating cells to bromodomain inhibition. J Exp Med. 2016;213(8):1459–77.CrossRef
8.
Zurück zum Zitat Ikeda K, Mason PJ, Bessler M. 3’UTR-truncated Hmga2 cDNAcauses MPN-like hematopoiesis by conferring a clonal growth advantage at the level of HSC in mice. Blood. 2011;117(22):5860–9.CrossRef Ikeda K, Mason PJ, Bessler M. 3’UTR-truncated Hmga2 cDNAcauses MPN-like hematopoiesis by conferring a clonal growth advantage at the level of HSC in mice. Blood. 2011;117(22):5860–9.CrossRef
9.
Zurück zum Zitat Bai J, Yokomizo-Nakano T, Kubota S, Sun Y, Kanai A, Iimori M, et al. Overexpression of Hmga2 activates Igf2bp2 and remodels transcriptional program of Tet2-deficient stem cells in myeloid transformation. Oncogene. 2021;40(8):1531–41.CrossRef Bai J, Yokomizo-Nakano T, Kubota S, Sun Y, Kanai A, Iimori M, et al. Overexpression of Hmga2 activates Igf2bp2 and remodels transcriptional program of Tet2-deficient stem cells in myeloid transformation. Oncogene. 2021;40(8):1531–41.CrossRef
10.
Zurück zum Zitat Nagpal S, Ghosn C, DiSepio D, Molina Y, Sutter M, Klein ES, et al. Retinoid-dependent recruitment of a histone H1 displacement activity by retinoic acid receptor. J Biol Chem. 1999;274(32):22563–8.CrossRef Nagpal S, Ghosn C, DiSepio D, Molina Y, Sutter M, Klein ES, et al. Retinoid-dependent recruitment of a histone H1 displacement activity by retinoic acid receptor. J Biol Chem. 1999;274(32):22563–8.CrossRef
11.
Zurück zum Zitat Yie J, Liang S, Merika M, Thanos D. Intra- and intermolecular cooperative binding of high-mobility-group protein I(Y) to the beta-interferon promoter. Mol Cell Biol. 1997;17(7):3649–62.CrossRef Yie J, Liang S, Merika M, Thanos D. Intra- and intermolecular cooperative binding of high-mobility-group protein I(Y) to the beta-interferon promoter. Mol Cell Biol. 1997;17(7):3649–62.CrossRef
12.
Zurück zum Zitat Srinivas S, Watanabe T, Lin CS, William CM, Tanabe Y, Jessell TM, et al. Cre reporter strains produced by targeted insertion of EYFP and ECFP into the ROSA26 locus. BMC Dev Biol. 2001;1:4.CrossRef Srinivas S, Watanabe T, Lin CS, William CM, Tanabe Y, Jessell TM, et al. Cre reporter strains produced by targeted insertion of EYFP and ECFP into the ROSA26 locus. BMC Dev Biol. 2001;1:4.CrossRef
13.
Zurück zum Zitat Abdallah MG, Niibori-Nambu A, Morii M, Yokomizo T, Yokomizo T, Ideue T, et al. RUNX1-ETO (RUNX1-RUNX1T1) induces myeloid leukemia in mice in an age-dependent manner. Leukemia. 2021;35:2983.CrossRef Abdallah MG, Niibori-Nambu A, Morii M, Yokomizo T, Yokomizo T, Ideue T, et al. RUNX1-ETO (RUNX1-RUNX1T1) induces myeloid leukemia in mice in an age-dependent manner. Leukemia. 2021;35:2983.CrossRef
14.
Zurück zum Zitat Ory DS, Neugeboren BA, Mulligan RC. A stable human-derived packaging cell line for production of high titer retrovirus/vesicular stomatitis virus G pseudotypes. Proc Natl Acad Sci USA. 1996;93(21):11400–6.CrossRef Ory DS, Neugeboren BA, Mulligan RC. A stable human-derived packaging cell line for production of high titer retrovirus/vesicular stomatitis virus G pseudotypes. Proc Natl Acad Sci USA. 1996;93(21):11400–6.CrossRef
15.
Zurück zum Zitat Yokomizo-Nakano T, Kubota S, Bai J, Hamashima A, Morii M, Sun Y, et al. Overexpression of RUNX3 represses RUNX1 to drive transformation of myelodysplastic syndrome. Cancer Res. 2020;80(12):2523–36.CrossRef Yokomizo-Nakano T, Kubota S, Bai J, Hamashima A, Morii M, Sun Y, et al. Overexpression of RUNX3 represses RUNX1 to drive transformation of myelodysplastic syndrome. Cancer Res. 2020;80(12):2523–36.CrossRef
16.
Zurück zum Zitat Cabezas-Wallscheid N, Klimmeck D, Hansson J, Lipka DB, Reyes A, Wang Q, et al. Identification of regulatory networks in HSCs and their immediate progeny via integrated proteome, transcriptome, and DNA methylome analysis. Cell Stem Cell. 2014;15(4):507–22.CrossRef Cabezas-Wallscheid N, Klimmeck D, Hansson J, Lipka DB, Reyes A, Wang Q, et al. Identification of regulatory networks in HSCs and their immediate progeny via integrated proteome, transcriptome, and DNA methylome analysis. Cell Stem Cell. 2014;15(4):507–22.CrossRef
17.
Zurück zum Zitat Pronk CJH, Rossi DJ, Månsson R, Attema JL, Norddahl GL, Chan CKF, et al. Elucidation of the phenotypic, functional, and molecular topography of a myeloerythroid progenitor cell hierarchy. Cell Stem Cell. 2007;1(4):428–42.CrossRef Pronk CJH, Rossi DJ, Månsson R, Attema JL, Norddahl GL, Chan CKF, et al. Elucidation of the phenotypic, functional, and molecular topography of a myeloerythroid progenitor cell hierarchy. Cell Stem Cell. 2007;1(4):428–42.CrossRef
18.
Zurück zum Zitat Dunham I, Kundaje A, Aldred SF, Collins PJ, Davis CA, Doyle F, et al. An integrated encyclopedia of DNA elements in the human genome. Nature. 2012;489(7414):57–74.CrossRef Dunham I, Kundaje A, Aldred SF, Collins PJ, Davis CA, Doyle F, et al. An integrated encyclopedia of DNA elements in the human genome. Nature. 2012;489(7414):57–74.CrossRef
19.
Zurück zum Zitat Huang H, Weng H, Sun W, Qin X, Shi H, Wu H, et al. Recognition of RNA N 6 -methyladenosine by IGF2BP proteins enhances mRNA stability and translation. Nat Cell Biol. 2018;20(3):285–95.CrossRef Huang H, Weng H, Sun W, Qin X, Shi H, Wu H, et al. Recognition of RNA N 6 -methyladenosine by IGF2BP proteins enhances mRNA stability and translation. Nat Cell Biol. 2018;20(3):285–95.CrossRef
20.
Zurück zum Zitat Copley MR, Babovic S, Benz C, Knapp DJHF, Beer PA, Kent DG, et al. The Lin28b-let-7-Hmga2 axis determines the higher self-renewal potential of fetal haematopoietic stem cells. Nat Cell Biol. 2013;15(8):916–25.CrossRef Copley MR, Babovic S, Benz C, Knapp DJHF, Beer PA, Kent DG, et al. The Lin28b-let-7-Hmga2 axis determines the higher self-renewal potential of fetal haematopoietic stem cells. Nat Cell Biol. 2013;15(8):916–25.CrossRef
21.
Zurück zum Zitat Degrauwe N, Schlumpf TB, Janiszewska M, Martin P, Cauderay A, Provero P, et al. The RNA binding protein IMP2 preserves glioblastoma stem cells by preventing let-7 target gene silencing. Cell Rep. 2016;15(8):1634–47.CrossRef Degrauwe N, Schlumpf TB, Janiszewska M, Martin P, Cauderay A, Provero P, et al. The RNA binding protein IMP2 preserves glioblastoma stem cells by preventing let-7 target gene silencing. Cell Rep. 2016;15(8):1634–47.CrossRef
22.
Zurück zum Zitat Cleynen I, Brants JR, Peeters K, Deckers R, Debiec-Rychter M, Sciot R, et al. HMGA2 regulates transcription of the Imp2 gene via an intronic regulatory element in cooperation with nuclear factor-κB. Mol Cancer Res. 2007;5(4):363–72.CrossRef Cleynen I, Brants JR, Peeters K, Deckers R, Debiec-Rychter M, Sciot R, et al. HMGA2 regulates transcription of the Imp2 gene via an intronic regulatory element in cooperation with nuclear factor-κB. Mol Cancer Res. 2007;5(4):363–72.CrossRef
23.
Zurück zum Zitat Matsuoka S, Oike Y, Onoyama I, Iwama A, Arai F, Takubo K, et al. Fbxw7 acts as a critical fail-safe against premature loss of hematopoietic stem cells and development of T-ALL. Genes Dev. 2008;22(8):986–91.CrossRef Matsuoka S, Oike Y, Onoyama I, Iwama A, Arai F, Takubo K, et al. Fbxw7 acts as a critical fail-safe against premature loss of hematopoietic stem cells and development of T-ALL. Genes Dev. 2008;22(8):986–91.CrossRef
24.
Zurück zum Zitat Reavie L, Gatta GD, Crusio K, Aranda-Orgilles B, Buckley SM, Thompson B, et al. Regulation of hematopoietic stem cell differentiation by a single ubiquitin ligase-substrate complex. Nat Immunol. 2010;11(3):207–15.CrossRef Reavie L, Gatta GD, Crusio K, Aranda-Orgilles B, Buckley SM, Thompson B, et al. Regulation of hematopoietic stem cell differentiation by a single ubiquitin ligase-substrate complex. Nat Immunol. 2010;11(3):207–15.CrossRef
25.
Zurück zum Zitat Laurenti E, Varnum-Finney B, Wilson A, Ferrero I, Blanco-Bose WE, Ehninger A, et al. Hematopoietic stem cell function and survival depend on c-Myc and N-Myc activity. Cell Stem Cell. 2008;3(6):611–24.CrossRef Laurenti E, Varnum-Finney B, Wilson A, Ferrero I, Blanco-Bose WE, Ehninger A, et al. Hematopoietic stem cell function and survival depend on c-Myc and N-Myc activity. Cell Stem Cell. 2008;3(6):611–24.CrossRef
26.
Zurück zum Zitat Ueda K, Ikeda K, Ikezoe T, Harada-Shirado K, Ogawa K, Hashimoto Y, et al. Hmga2 collaborates with JAK2V617F in the development of myeloproliferative neoplasms. Blood Adv. 2017;1(15):1001–15.CrossRef Ueda K, Ikeda K, Ikezoe T, Harada-Shirado K, Ogawa K, Hashimoto Y, et al. Hmga2 collaborates with JAK2V617F in the development of myeloproliferative neoplasms. Blood Adv. 2017;1(15):1001–15.CrossRef
27.
Zurück zum Zitat Sgarra R, Maurizio E, Zammitti S, Lo Sardo A, Giancotti V, Manfioletti G. Macroscopic differences in HMGA oncoproteins post-translational modifications: C-terminal phosphorylation of HMGA2 affects its DNA binding properties. J Proteome Res. 2009;8(6):2978–89.CrossRef Sgarra R, Maurizio E, Zammitti S, Lo Sardo A, Giancotti V, Manfioletti G. Macroscopic differences in HMGA oncoproteins post-translational modifications: C-terminal phosphorylation of HMGA2 affects its DNA binding properties. J Proteome Res. 2009;8(6):2978–89.CrossRef
Metadaten
Titel
The acidic domain of Hmga2 and the domain’s linker region are critical for driving self-renewal of hematopoietic stem cell
verfasst von
Yuqi Sun
Sho Kubota
Mihoko Iimori
Ai Hamashima
Haruka Murakami
Jie Bai
Mariko Morii
Takako Yokomizo-Nakano
Motomi Osato
Kimi Araki
Goro Sashida
Publikationsdatum
24.01.2022
Verlag
Springer Singapore
Erschienen in
International Journal of Hematology / Ausgabe 4/2022
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-021-03274-9

Neu im Fachgebiet Onkologie

Kein (großer) Schutz vor Kolorektalkarzinom-Rezidiven durch ASS

Die erste Phase-3-Studie zum Nutzen von ASS in der adjuvanten Therapie des kolorektalen Karzinoms ist negativ verlaufen. Das abschließende Urteil über eine Sekundärprävention mit ASS ist trotzdem noch nicht gefallen.

Frühe CLL-Therapie: BTK-Hemmer verlängert EFS und PFS, aber nicht OS

Auch nach sechs Jahren ergibt sich kein Überlebensvorteil einer Therapie mit dem BTK-Hemmer Ibrutinib für Menschen mit frühem CLL-Stadium und erhöhtem Progressionsrisiko. Die Progressionsrate wird mit der Behandlung jedoch um über 80% gesenkt.

Adjuvantes Atezolizumab ohne Nutzen bei frühem TNBC

Patientinnen mit frühem triple-negativem Brustkrebs profitieren nach der Operation offenbar nicht von einer Zugabe des PD-L1-Hemmers Atezolizumab zur adjuvanten Standardchemotherapie. Die Studie, die das untersucht hat, wurde vorzeitig abgebrochen. Was könnte die schlechte Wirksamkeit erklären?

Brustkrebstherapie: zu wenig Aufklärung über Nebenwirkungen?

Ergebnisse eines internationalen Surveys legen nahe, dass die Aufklärung über Nebenwirkungen einer Brustkrebstherapie häufig unzureichend ausfällt bzw. zu spät erfolgt.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.